MetaVia Inc. MTVA
As ofNov 20, 2026, 10:10 AM EST
- YTD
- -87.29%
- 1 year
- -85.32%
- Market cap
- 7.25M
- EPS (ttm)
- -2.78
- Shares out
- 8.62M
- YTD return
- -87.29%
- 1-year return
- -85.32%
- 50-day average
- 2.50
- 200-day average
- 3.54
- Enterprise value
- -7.74M
- Price / book
- 1.08
- Volume
- 7.78K
- Avg volume
- 113.49K
- Open
- 1.08
- Previous close
- 1.09
- Day's range
- 1.07 – 1.08
- 52-week range
- 0.966 – 13.42
- Beta
- -0.28
- Analysts
- Strong Buy
- Price target
- 17.33 (+1519.9%)
Key statistics
- Total cash
- 21.67M
- Total debt
- 154.00K
- Return on equity
- -160.76%
- Short % of float
- 0.67%
Fundamental scorecard
4 of 25 checks passed on MTVA’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- metaviatx.com
News
MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726 Metavia Announces Preclinical Data From Head-To-Head Study Comparing Novel GLP-1 DA-1726 With Retatrutide; Sees Statistically Significant Increase In Liver And Circulating FGF21 Expression; Plans Phase 2 Study In MetALD And ALD H2 2027
MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026 MetaVia Q3 EPS $(0.69) Beats $(0.73) Estimate
MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update
MetaVia's Potential Drug Candidate Cuts Serum Uric Acid and Liver Fat MetaVia Announces Interim Data From Part 3B Of Its Phase 1 Clinical Trial Of DA-1726 Targeting Both GLP-1 And Glucagon Receptors; Results Demonstrate 68% Placebo-Adjusted Reduction In Liver Fat And 13.5% Placebo-Adjusted Body Weight Reduction Following 16 Weeks Of Once-Weekly DA-1726 Treatment In Otherwise Healthy Adults With Obesity; Plans Phase 2 For H2 2027
MetaVia To Report Data From Its Phase 1 Clinical Study Of DA-1726 At Precision Liver Symposium 2026
12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on MTVA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONG-A ST CO., LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 11, 2024 | 5,347,790 |
| GLICKMAN MARK A | Director | Stock Award(Grant) | Jun 6, 2024 | 9,740 |
| GROVES JASON L | Director | Stock Award(Grant) | Jun 6, 2024 | 17,552 |
| KIM HYUNG HEON | Chief Executive Officer | Stock Award(Grant) | Aug 10, 2023 | 625,064 |
| KIM NA YEON | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 26, 2023 | 302,013 |
| KOVEN ANDREW IAN | Director | Stock Award(Grant) | Jun 6, 2024 | 17,552 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.84% | 848,000 | 1.38M | Sep 29, 2024 |
| Affinity Asset Advisors, Llc | 1.04% | 89,222 | 145.43K | Sep 29, 2024 |
| Vanguard Group Inc | 0.70% | 60,452 | 98.54K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.38% | 32,574 | 53.09K | Sep 29, 2024 |
| Ferguson Wellman Capital Management, Inc. | 0.18% | 15,670 | 25.54K | Sep 29, 2024 |
| State Street Corporation | 0.18% | 15,633 | 25.48K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.38% | 32,432 | 52.86K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.33% | 28,020 | 45.67K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.23% | 19,569 | 31.90K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 4,747 | 7.74K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 4,751 | 7.74K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 4,667 | 7.61K | Oct 30, 2024 |
